Company: GEHC
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001628280-25-017240
Chunk: 34

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 34
---
 proxy statement, is hereby APPROVED.”                                                                                                                                                                                                                                                                                                                                      |
|                                                                            |     | The Board recommends a vote FOR the say-on-pay proposal |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

#### 36GE HEALTHCARE 2025 PROXY STATEMENT

#### Compensation

### Compensation Discussion and Analysis
This Compensation Discussion and Analysis (“CD&A”) describes the compensation awarded to our NEOs for 2024. This includes key elements of our executive compensation program, and the philosophy and rationale behind the Compensation Committee’s decisions.

The Compensation Committee reviewed and approved 2024 compensation decisions for our executives within the Compensation Committee’s purview, including our NEOs:

|                                       |     |                                            |     | NEOs                                 |     |                                         |     |                            |
| President and Chief Executive Officer 
 Peter J. Arduini                      |     | Vice President and Chief Financial Officer 
 James Saccaro                              |     | Chief Science and Technology Officer 
 Taha Kass-Hout                       |     | General Counsel and Corporate Secretary 
 Frank R. Jimenez                        |     | President and CEO, Imaging 
 Roland Rott(1)             |

(1) Mr. Rott was appointed President and CEO, Imaging effective July 1, 2024, replacing Jan Makela who left the Company.

#### Executive Summary

### Business Results
We strive to attract, retain, and motivate top executive talent who create long-term value for our stockholders through execution of the three pillars of our business strategy: Precision Care, Growth Acceleration, and Business Optimization, with a foundation of People, Patients, and Culture. A summary of our 2024 financial performance is set forth below:

• Revenues were $19.7 billion and Organic revenue* was $19.7 billion; Revenues increased 1% year-over-year and 1% on an Organic* basis.

• Net income attributable to GE HealthCare was $2.0 billion and Adjusted earnings before interest and taxes (“Adjusted EBIT”)* were $3.2 billion.

• Diluted earnings per share - continuing operations were $4.34 and Adjusted earnings per share* were $4.49.

• Cash from operating activities - continuing operations was $2.0 billion and Free cash flow* was $1.6 billion.

We believe that the compensation paid for 2024 aligns well to the financial results we achieved for the year.

* Non-GAAP financial measure. See the Appendix for additional information and definitions of these non-GAAP financial measures.